Biogen (BIIB)
(Delayed Data from NSDQ)
$224.94 USD
+4.87 (2.21%)
Updated May 31, 2024 04:00 PM ET
After-Market: $224.85 -0.09 (-0.04%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth C Momentum B VGM
Brokerage Reports
Biogen Inc. [BIIB]
Reports for Purchase
Showing records 641 - 660 ( 803 total )
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Our Thoughts on Aducanumab and Solanezumab Data From CTAD
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
What Does the Solanezumab Miss Mean for Aducanumab
Provider: H.C. Wainwright & Co., Inc.
Analyst: DAVIS C
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
2016 World Orphan Drug Congress Recap: Emerging Trends in Rare Disease Therapeutics
Provider: Rodman & Renshaw, Co.
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
A Means to Minimize ARIA-E? We Look to Interim Analysis of Cohorts 8 and 9 of PRIME at CTAD
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
An Update From the World Muscle Society Congress: ENDEAR and NURTURE
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
A Closer Look at Solanezumab Ahead of EXPEDITION 3 Readout
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
We Continue to View PRIME as a Positive Demonstration of Aducanumab?s PK/PD
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A